Further in vivo studies will elucidate effects of inhibiting TLR9-mediated signaling, which should trigger differentiation of cancer-propagating cells into tumor cells with potentially greater sensitivity to standard therapies [43]. The gene discussed is TLR9; the disease is neoplasm.